351 results about "Protein A" patented technology

The invention provides a method set system for predicting dynamic structure change of protein A beta 42 based on a deep learning method. The method comprises the following steps: extracting PDB of each frame from a molecular dynamics track; the 2DIR of each PDB is calculated; splitting the PDB according to the functional characteristic region; an alpha-carbon distance matrix distance map of each PDB is calculated, and an alpha-carbon distance matrix distance map of each PDB is calculated; according to the trained deep learning model, predicting an alpha-carbon distance matrix distance map of each region; constructing a protein three-dimensional structure; merging fragments and comparing the fragments with a three-dimensional structure: aligning the optimized three PDB segments, and merging the three PDB segments into a complete PDB protein three-dimensional structure; and finally, solving the RMSD error between the predicted PDB and the real PDB. According to the method, a division and treatment strategy is adopted, three sections of different regions in a protein structure are predicted by utilizing 2DIR, and finally, a three-dimensional structure is successfully constructed. According to the method, a new method is provided for exploring the structure and dynamic change of the Abeta42, a new view angle for researching the Alzheimer's disease is opened up, and important information is also provided for drug design.

A system and method for generating thermostable variants of a protein is disclosed. The system receives a three-dimensional structure of a target protein and identifies mutable regions, including solvent-exposed residues and loop regions. Conserved and active site residues are excluded from mutation through a fixed-position mask. A message-passing neural network (MPNN) generates mutant sequences at unmasked positions, executed under multiple temperature parameters. Design scores based on Shannon entropy and log probability are computed, and high-confidence variants are selected. Predicted structures for selected variants are evaluated using structural and sequence-based features to compute stability scores. A ranked list of thermostable variants is generated. Top candidates undergo molecular dynamics simulations to compute dynamic metrics such as RMSD, radius of gyration, SASA, and ddG, and are re-ranked accordingly. The system enables accurate, constraint-driven protein design with high structural and functional fidelity, suitable for industrial and therapeutic applications.

The invention belongs to the technical field of biological detection, and discloses a kit and a method for quantitatively detecting residual quantity of host cell protein of pichia pastoris in order to solve the problems of limit of quantitation and low detection sensitivity of an existing detection method. According to the present invention, the empty plasmid without the recombinant human serum albumin gene is introduced into the pichia pastoris, and purification is performed by combining the Protein A chromatographic column and the host cell protein coupling affinity column, such that the prepared polyclonal antibody can be effectively used for the quantitative detection of the residual amount of the pichia pastoris host cell protein in the biological product; the kit formed by the polyclonal antibody has good accuracy and repeatability on the quantitative detection of the host cell protein residues in the pichia pastoris source biological products, the quantification limit is 0.2 ng / mL, and the kit provided by the invention can meet the quantitative detection of the host cell protein residues in all the pichia pastoris source biological products.

The present invention provide novel immunofiber compositions for protein or peptide purification and simple and cost-efficient methods and systems using these compositions. In some embodiments, the immunofibers comprise a customized Z-33 peptide derived from Staphylococcus aureus Protein A which is used to construct immuno-amphiphile molecules that assemble into immunofibers in aqueous solution with bioactive epitopes on the surface and have peptide or protein binding ability.

The invention provides a monoclonal antibody capable of specifically recognizing a specific metabolic fragment of human amyloid protein and application of the monoclonal antibody, and belongs to the technical field of genetic engineering. The invention provides a hybridoma cell strain AB5H, and the preservation number of the hybridoma cell strain AB5H is CCTCC (China Center For Type Culture Collection) NO: C201255. The hybridoma cell strain AB5H disclosed by the invention can secrete a monoclonal antibody which has relatively high activity and can specifically recognize human beta amyloid protein A beta 40; the monoclonal antibody is high in titer, can be used as a capture antibody, and is used for preparing a human Abeta40 protein quantitative detection kit and quantitatively detecting the content of Abeta40 in cerebrospinal fluid and blood, so that the detection result deviation caused by the fact that the content of Abeta40 in peripheral blood is easily influenced by metabolism, sample treatment conditions and methods and individual differences is overcome, and the detection accuracy is improved. The variation degree of a detection result is reduced, so that a judgment boundary value of a blood A beta detection result is conveniently obtained, and AD early diagnosis is realized.

A method and apparatus for inoculating a bioreactor with a C1-fixing strain is disclosed. In particular, the present disclosure relates to the cost-efficient methods and apparatus for inoculating a bioreactor with a C1-fixing strain for production of protein, such as single cell protein or cultured protein, by microbial fermentation of a gaseous substrate.

The invention belongs to the technical field of enzyme engineering, and discloses a high-activity and high-stability PET hydrolase mutant and application thereof. The high-activity and high-stability PET hydrolase mutant is a protein A, a protein B or a protein C, wherein the protein A is obtained by mutating the 132 amino acid of wild cutinase TfCut from glutamine Q to lysine K; the protein B is obtained by mutating the 244th and 293rd amino acids into cysteine C on the basis of the protein A; protein C is a fusion protein containing protein A or protein B. The modified enzyme breaks through a trade-off mechanism of enzyme catalytic activity and stability, and the activity and thermal stability of the modified enzyme are greatly improved, so that the industrial application value of the PET hydrolase in the aspect of PET degradation is improved.

The invention discloses a kit for auxiliary diagnosis of Alzheimer's disease and a preparation method and application thereof, and relates to the field of medical detection. The kit for auxiliary diagnosis of the Alzheimer's disease comprises a magnetic particle solution coated with a capture antibody, an enzyme-labeled antibody compound, a cleaning solution and a luminous substrate, the magnetic particle solution coated with the capture antibody comprises magnetic particles connected with a first antibody, and the first antibody is specifically combined with a biomarker; the enzyme-labeled antibody compound comprises a second antibody coupled with an enzyme, and the second antibody and the first antibody are specifically combined with the same biomarker; the magnetic particles comprise carboxyl magnetic beads, the carboxyl magnetic beads are coated with Protein A, and the Protein A is connected with a first antibody. By optimizing the coupling process of the antibody, the problems of poor biomarker detection sensitivity and low efficiency of the traditional detection technology are solved, and redundant inspection items for early diagnosis of the Alzheimer's disease and other neurodegenerative diseases are reduced.

The invention discloses a light-activated chemiluminescence method for detecting myxovirus resistant protein A, and belongs to the technical field of marker detection. The invention provides a detection system of a myxovirus resistance protein A. The detection system comprises an MxA Ab1-acceptor microsphere complex and an MxA Ab2-donor microsphere complex. The invention provides a detection system of myxovirus resistance protein A. The detection system is used for detecting MxA, is homogeneous and washing-free, is simple and convenient to operate and high in sensitivity, and has a wide linear range. Experiments prove that the detection limit of the myxovirus resistant protein A antigen is 1.37 ng / mL, and the linear range is 5-1229 ng / mL. The kit is high in specificity and repeatability, can be used for rapidly detecting virus infection markers, and has application value.

The invention provides a synthesis method of adsorption resin for removing immune globulin, and relates to a high polymer material synthesis technology, polyethylene glycol (PEG) or sulfobetaine (SBMA) is grafted through RAFT polymerization, the thickness of a grafting layer is 50-150nm, the nonspecific adsorption capacity of albumin is less than 5ng / cm < 2 >, photosensitive groups (such as phenyl azide) and ultraviolet light (254nm) are introduced to trigger crosslinking, and the coating shedding rate is less than 0.5% / time. According to the present invention, the cyclic stability is improved by 2 times, the Protein A directional capture antibody is grafted on the surface of the acrylic resin grafted with the polyethylene glycol or sulfobetaine, the IgG adsorption capacity achieves 150 mg / g, the specificity is more than 95%, the polyethylene glycol (PEG) is grafted on the surface of the magnetic particle by using ATRP / RAFT controllable polymerization, the organic solvent use amount is reduced by more than 80%, and the product adsorption capacity achieves 150 mg / g.

The present invention relates to binding molecules comprising an optimised Fc domain, wherein the optimised Fc domain comprises one or more mutations which decrease protein A binding, increase protein A binding, or improve stability. The present invention also relates to methods of purifying heterodimeric proteins comprising an optimised Fc domain comprising one or more mutations which decrease protein A binding or increase protein A binding.

The invention discloses a preparation method of a monomeric protein and hydrophobic transmembrane protein complex, which comprises the following steps: 1) preparing a protein A containing the monomeric protein, the C end of the monomeric protein in the protein A having a connection sequence for connecting with the hydrophobic transmembrane protein; the connecting sequence comprises at least two amino acids; preparing a protein B containing a hydrophobic transmembrane protein monomer; and 2) connecting the protein A with the protein B, and polymerizing the hydrophobic transmembrane protein monomers in the plurality of protein B to form the hydrophobic transmembrane protein, thereby obtaining the monomeric protein and hydrophobic transmembrane protein complex.

A pharmaceutical composition for enhancing radiation therapy, containing a fusion protein dimer is disclosed. The fusion protein dimer includes an IL-2 protein and a CD80 protein. A method of radiation therapy for cancer, using the composition is also disclosed. The composition for enhancing radiation therapy may increase the effect of radiation therapy in cancer treatment.

Provided herein are methods for purifying polypeptides (e.g., antibodies) comprising an Fc region by Protein A chromatography; methods for using wash solutions comprising benzoate and / or benzyl alcohol during Protein A chromatography; and methods for conditioning the harvest using sodium benzoate prior to Protein A chromatography. [Selected Figure] Figure 1

A method for treating or alleviating autoimmune encephalitis with an effective amount of a medicament targeting Blys and / or APRIL. Results show that the effective amount of the medicament targeting Blys and / or APRIL exhibits a good safety profile and a relatively good therapeutic effect in the process of treating or alleviating autoimmune encephalitis.

The invention provides a method for detecting an anti-C1 esterase inhibitor neutralizing antibody in a biological sample, and the method mainly utilizes the characteristic that protein A resin is combined with an Fc segment of the antibody to capture the antibody (containing the anti-C1 esterase inhibitor neutralizing antibody), so that the C1 esterase inhibitor and complement component 1s (C1s) in the biological sample after thermal inactivation are removed; furthermore, an antibody (containing a neutralizing antibody) or an anti-C1 esterase inhibitor compound on the protein A resin is subjected to acid dissociation through an acidolysis solution, so that not only can the anti-C1 esterase inhibitor neutralizing antibody existing in a free form in a biological sample be detected, but also the anti-C1 esterase inhibitor neutralizing antibody existing in a combined form in the biological sample can be detected.

To provide a glycan preparation method for preparing labeled glycans quickly from glycoproteins.SOLUTION: A glycan preparation method comprises: a releasing step in which a glycosidase is allowed to act on a glycoprotein immobilized on a solid phase in a container to obtain a released product containing glycans; and a labeling step in which a labeling reagent is added to the released product in the container to obtain a labeled product containing labeled glycans, wherein the glycoprotein is an antibody, the solid phase has on its surface a ligand selected from the group consisting of protein A, protein G, protein L, protein H, protein D, and protein Arp, and the labeling reagent comprises a reducer, a solution and at least one selected from the group consisting of 8-aminopyrene-1,3,6-trisulfonic acid, a sodium salt thereof, and 9-aminopyrene-1,4,6-trisulfonic acid.SELECTED DRAWING: None

Disclosed herein are improved methods for quantifying monoclonal antibody (mAb) titer using Protein A affinity High-Performance Liquid Chromatography (HPLC). The methods address inaccuracies caused by mAb adsorption to sample vial surfaces by incorporating a surfactant into the mobile phase used for sample dilution. This approach enhances the accuracy, linearity, and robustness of the titer assay, making it suitable for process control and quality assessment in biopharmaceutical development and manufacturing. The methods can be applied as a platform approach for various mAb products.

The present disclosure relates to the treatment of cancer. In particular, the present disclosure provides novel therapeutic antibodies that target MHC Class I Chain-Related Protein A (MICA) in a manner that reduces the ability of a tumor cell to escape immune clearance mediated by the natural killer group 2D (NKG2D) receptor.

A process for the manufacture of glycosylated p75NTR neurotrophin binding protein (NBP)-Fc fusion protein, comprising: a p75NTR(NBP) portion, having at least 85% sequence identitywith Seq ID No. 2; and an immunoglobulin Fc portion. wherein, the p75NTR(NBP) and Fc portions are connected via a linker, the linker comprises a peptide of formula Gx, where x is 1, 2, 3, 4, 5 or 6 wherein the linker does not comprise or consist of the sequence GGGGS, characterised by expression from CHO cells, wherein cells are harvested within earlier of 30 hours of cell culture viability reaching 75% or, 12 days post inoculation.

A new technique for improving the secretion production of a heterologous protein by a coryneform bacterium is developed, and thus a method for the secretion production of a heterologous protein is provided. A coryneform bacterium having a secretion production ability of a heterologous protein and modified to maintain a phoS gene having a specific mutation is cultured to produce a heterologous protein by secretion.

The invention discloses a chimeric gene engineering nano vesicle for removing pathogenic antibodies as well as a preparation method and application of the chimeric gene engineering nano vesicle, and belongs to the technical field of biology. According to the invention, a stable transfection cell line of a protein A / G gene is constructed through lentiviral particle transfection, so that the protein A and the protein G can be stably expressed. The fusion protein A / G can overcome the defect of weak binding capacity of pure protein A and IgG3, and the adsorption effect of the antibody IgG is improved. The PLGA nanoparticles with relatively uniform particle size are adopted as the core of the target vesicle and are mixed with the engineered cell membrane broken by extrusion to promote self-assembly of the cell membrane and form an extracellular vesicle simulant, so that the stability of the target nano vesicle is improved. The prepared and separated nano vesicles can be applied to in-vivo adsorption and antibody removal, the biological safety is good, and the dialysis indwelling catheter operation risk in the use process of an existing immunoadsorption column and the risks of bleeding, allergy and the like in the treatment process are avoided.

The present application provides an isolated antigen-binding protein, comprising: a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain specifically binds to TNF-like protein A (TL1A), and the first antigen binding domain and the second antigen binding domain are different.

The present invention provides D-dimer antibodies and their applications and D-dimer detection products, wherein the D-dimer antibodies are selected from protein a and / or protein b, and the amino acid sequences of the heavy chain complementary determining region and the light chain complementary determining region of the antibody are defined. The D-dimer antibodies have good specificity, high biological activity, strong stability, and high affinity with D-dimer, and can be used to prepare products for detecting D-dimer. The D-dimer detection test strips and detection kits provided by the present invention have the advantages of simple operation, rapid response, high sensitivity, strong specificity, suitability for rapid on-site detection, and economical and practical, and can be rapidly screened, and provide auxiliary diagnosis for diseases such as deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation quickly, accurately, and safely, so that patients can be diagnosed and treated early.

This invention generally relates to methods for enriching antibodies of interest. Specifically, this invention relates to enriching therapeutic antibodies from upstream cell culture processes using protein A chromatography in the form of a centrifugal column for product quality property profiling analysis.

The present disclosure provides a nanobody platform having a high affinity purification on protein A, wherein the nanobodies may incorporate diverse bioactive peptides, lipid or glycoside in its CDR1 and / or CDR3 regions. The present disclosure also provides a peptide-modified nanobody comprising non-toxic bioactive peptides and that exhibit potent anti-tumor activity. Moreover, the peptide-modified nanobody is able to be combined with other technologies, such as but not limited to bispecific antibodies and antibody-drug conjugates. Further, the present disclosure also provides production processes of the nanobodies and their use as a treatment and diagnostic agents.

The invention provides methods for microbial bioburden reduction of various chromatography matrices, including bioburden reduction in the context of large-scale Protein A-based affinity chromatography columns.

The present disclosure relates to a method for improving the quality of glycosylated antibody drug conjugates (DAR distribution, stability, etc.) using activated carbon. Specifically, the present disclosure employs hydrophobic interaction chromatography (HIC) column, protein A chromatography, activated carbon stirring, and buffer exchange, alone or in series, to remove free glycosyltransferases. As a result, the purity of the glycosylated antibody drug conjugates is improved, and the degradation of the antibody drug conjugates is prevented. Ultimately, the drug substance (DS) of OBI-902 (anti-TROP2 antibody drug conjugate) and OBI-904 (anti-Nectin-4 antibody drug conjugate) is further determined.

The invention discloses an efficient purification process of a bispecific antibody and a special chromatography system thereof. The efficient purification process of the bispecific antibody comprises the following steps: pretreatment: performing 0.22 mu m microfiltration on a cell culture supernatant to remove cell debris, and performing deep filtration to reduce turbidity to be less than or equal to 1NTU so as to reduce subsequent chromatography medium pollution; carrying out improved Protein A affinity chromatography, namely carrying out affinity chromatography by adopting an agarose medium modified by a recombinant Protein A ligand, taking 20mM Tris-HCl as a loading buffer solution, and taking the pH value of the loading buffer solution as 7.4, taking 100mM citric acid as an elution buffer solution, and taking the pH value of the elution buffer solution as 3.2-3.5; performing mixed mode chromatography: adopting a composite mode medium containing a benzamidine functional group, taking 50mM sodium phosphate as a buffer solution, adjusting the pH value to 6.0-6.5, adjusting the NaCl concentration to 0.1-0.3 M, and specifically removing a double-antibody polymer and a mismatched isomer by utilizing a hydrophobic effect and an ion exchange synergistic effect; and performing nanoscale filtration and terminal treatment: removing viruses by adopting a virus filtration membrane with the aperture of 30nm, and performing 0.22 mu m sterile filtration to obtain a final product. According to the process, the purification efficiency, the yield and the product purity are remarkably improved, and the process is suitable for efficient purification of the bispecific antibody.

A kit for quantitative analysis of C-reactive protein (CRP) according to an embodiment of the present application may comprise: a first composition comprising a hemolytic agent for hemolyzing at least a portion of blood cells in a blood sample; and a second composition comprising an anti-CRP antibody for the antigen-antibody reaction of the CRP contained in the hemolyzed sample. The CRP quantitative analysis kit of the present application can provide a stabilizer which enables a solid-phase dry anti-CRP antibody to be sufficiently redissolved to participate in an immune reaction, so that quantitative analysis of CRP can be highly accurately and accurately performed in a wide concentration range, and storage stability is improved.